{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-046134","form_type":"8-K","ticker":null,"cik":"0001178879","company_name":"AMICUS THERAPEUTICS, INC.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.941667+00:00","generated_at":"2026-05-16T12:31:39.290465+00:00","sec_items":["1.01","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Amicus agrees to be acquired by BioMarin for $14.50 per share in cash","bullets":["Merger consideration $14.50 per share; expected to close in Q2 2026.","Termination fee of $175M payable by Amicus in certain termination scenarios.","Transaction requires shareholder approval, HSR and foreign antitrust clearances.","No-solicit restrictions apply; Amicus board may consider superior proposals under fiduciary duty.","Bylaws amended to add exclusive forum provision (Item 5.03)."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-046134","json":"https://secwatch.observer/filing/0001140361-25-046134.json","markdown":"https://secwatch.observer/filing/0001140361-25-046134.md","text":"https://secwatch.observer/filing/0001140361-25-046134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/0001140361-25-046134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/ef20061157_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:31:39.290465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73ca56e4d3dc157858e8170a6d547419fee8c39b","claim":"AMICUS THERAPEUTICS, INC.: On December 19, 2025, the Board approved and adopted a Forum Selection Amendment to the Company's existing By-laws, adding a new Section 6.5 to Article VI (effective 2025-12-19).","evidence_excerpt":"On December 19, 2025, the Board approved and adopted an amendment (the “ Forum Selection Amendment ”) to the Company’s existing By-laws that amends Article VI to include a new Section 6.5.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/0001140361-25-046134-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-12-19"}],"fact_type":"governance_change"},{"claim_id":"de6d7971a4733d6da7d8c0f00b25a275ac7c2c31","claim":"AMICUS THERAPEUTICS, INC. entered into Agreement and Plan of Merger with BioMarin Pharmaceutical Inc. valued at $14.50 per Share in cash (effective 2025-12-19).","evidence_excerpt":"On December 19, 2025, Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with BioMarin Pharmaceutical Inc., a Delaware corporation (“ Parent ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ Merger Sub ”), providing for the merger of Merger Sub with and into the Company (the “ Merger ”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178879/000114036125046134/0001140361-25-046134-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"BioMarin Pharmaceutical Inc."},{"label":"Value","value":"$14.50 per Share in cash"},{"label":"Effective","value":"2025-12-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}